MSCS

EC-Council University Ranked Top 10 in Online Masters of Cybersecurity by Fortune® Education

Retrieved on: 
Wednesday, April 17, 2024
Online, EC-Council, University, MSCS, CHFI, Curriculum, Duke University, Indiana University, National initiative, Faculty, CEH, Student, Specialization, Nursing

Albuquerque, New Mexico, April 17, 2024 (GLOBE NEWSWIRE) -- EC-Council University has been named in Fortune® elite ranking of the Best Online Master's in Cybersecurity for 2024, alongside esteemed institutions like the University of California – Berkeley, Duke University, Indiana University, and the University of Arizona.

Key Points: 
  • Albuquerque, New Mexico, April 17, 2024 (GLOBE NEWSWIRE) -- EC-Council University has been named in Fortune® elite ranking of the Best Online Master's in Cybersecurity for 2024, alongside esteemed institutions like the University of California – Berkeley, Duke University, Indiana University, and the University of Arizona.
  • With a 92% retention rate and graduating class of 100 students in 2022-2023, EC-Council University has the second largest cohort of students for its Master’s program in cybersecurity among Fortune® top 20.
  • Each specialization has well-defined job prospects, derived from the National Initiative of Cybersecurity Education (NICE) published by the National Institute of Standards and Technology.
  • Lata Bavisi, President of EC-Council University, expressed gratitude for the recognition, stating, "We are honored to have EC-Council University acknowledged by Fortune® in the top 10 of the online master's program in cybersecurity.

Crnic Institute Awarded Anschutz Acceleration Initiative Grant for Pioneering Research Aimed at Improving the Health of Children with Down Syndrome

Retrieved on: 
Thursday, January 18, 2024
Assistant professor, Network affiliate, Anschutz Medical Campus, Research, Database, AAI, Congress, Philip Anschutz, Associate professor, Health, Rheumatology, JAK, CO, Anschütz, University, MSCS, Quality of life, Chromosome, NIH, Colorado State University, Doctor of Philosophy, T21, Crnić, Inflammation, Doctor of Psychology, Clinical trial, Anna, Immune system, Pharmaceutical industry

“Receiving this grant is deeply gratifying,” says Dr. Joaquín Espinosa, Professor in Pharmacology and Executive Director of the Crnic Institute.

Key Points: 
  • “Receiving this grant is deeply gratifying,” says Dr. Joaquín Espinosa, Professor in Pharmacology and Executive Director of the Crnic Institute.
  • “Everyone at the Crnic Institute, GLOBAL and all our Affiliates have worked so hard in the last ten years to take our remarkable findings from the Petri dish and parlay that into benefit for people with Down syndrome.
  • Key outstanding questions specific to individuals with Down syndrome will be addressed:
    What are the impacts of interferon hyperactivity during early childhood?
  • From over 165 letters of intent and ultimately 56 full proposals, 9 research projects were funded.

4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis at 2023 NACFC

Retrieved on: 
Wednesday, November 1, 2023
Principal, Gene editing, Pulmonology, VG, AAV, Pneumonitis, Aes, SVP, National Jewish Health, Valencia CF Foundation, Safety, Conference, Idiopathic pulmonary fibrosis, Inflammation, Pediatrics, MSCS, Quality of life, Disease, Clinical trial, Cystic fibrosis, Hospital, Bronchospasm, Cohort, Pharmaceutical industry, Vaccine, CFTR, Medicine

ET

Key Points: 
  • ET
    EMERYVILLE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a genetic medicines company with three novel, highly targeted next generation AAV vectors currently in human clinical studies, today announced interim data from the Phase 1/2 AEROW clinical trial evaluating aerosolized 4D-710 for treatment of cystic fibrosis lung disease.
  • Results will also be presented at the 2023 North American Cystic Fibrosis Conference (NACFC) in both plenary and symposium sessions on November 2-3.
  • “We are pleased with the safety and tolerability of 4D-710 in participants in the AEROW study to date.
  • Initial results from the AEROW study showed that 4D-710 resulted in CFTR expression in lung airways that significantly exceeded our target profile.

Museum’s Freedom Award experience full of inspiration and education

Retrieved on: 
Friday, October 20, 2023
National Civil Rights Museum, Carson, National Hindu Students' Forum, Food, Main Street, Freedom, History, Freedom Award, Golden Joystick Awards, Red carpet, MSCS, Medicine, Museum, Student, Magic, Orpheum, Music, Police, Dreaming Award, Social change, 2008 in red carpet fashion, Nursing, Tourism

The Freedom Award experience kicked off with the Student Forum which was held in person for the first time since 2019 before 2,000 students with a livestream option for hundreds of students beyond the area.

Key Points: 
  • The Freedom Award experience kicked off with the Student Forum which was held in person for the first time since 2019 before 2,000 students with a livestream option for hundreds of students beyond the area.
  • Local students participated and performed during the program, as they learned more about civil and human rights and the personal journeys of this year’s Freedom Award honorees.
  • The museum’s Keeper of the Dream Award was bestowed upon three local students Hannah Glenn, Jade Mitchell, and Ira Sharma.
  • “As we honor these outstanding individuals, let us reflect on their passion and compassion for their fellow human beings.

Roche to showcase next-generation diagnostic solutions at the American Association of Clinical Chemistry 2023 Clinical Lab Expo

Retrieved on: 
Wednesday, July 19, 2023
RFP, Partnership, Mayo Clinic, Medical laboratory, University, AACC, Heart failure, STRONG, FACC, Personalized medicine, Pathology, Immunoassay, MSCS, Mass spectrometry, PST, Sale, Science, Maryland School, ROG, RO, University of Texas Southwestern Medical Center, CCM, FAHA, ISE, Internal medicine, Ion-selective electrode, University of Maryland School of Medicine, Cardiology, Health, Alzheimer's disease, Medicine, Fine chemical, Pharmaceutical industry, Communications satellite

The Roche exhibit booth and Roche Idea Lab series featuring industry experts will highlight how our commitments to science, operational simplicity and partnership can improve patient care.

Key Points: 
  • The Roche exhibit booth and Roche Idea Lab series featuring industry experts will highlight how our commitments to science, operational simplicity and partnership can improve patient care.
  • INDIANAPOLIS and ANAHEIM, Calif., July 19, 2023 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) will showcase a science-driven and patient-centric exhibit at the 2023 American Association of Clinical Chemistry (AACC) Scientific Meeting and Clinical Lab Expo, July 23-27 in Anaheim, California.
  • These systems can provide healthcare communities with the future benefit of an extended diagnostic platform offering clinical chemistry, molecular diagnostics, immunoassays and mass spectrometry.
  • For more information about Roche's participation at AACC 2023 and Roche Idea Lab programming, visit AACC.roche.com .

Carmot Therapeutics Highlights Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 83rd American Diabetes Association Scientific Sessions

Retrieved on: 
Saturday, June 24, 2023
Hyperinsulinemia, Insulin, Obesity, American Diabetes Association, MOA, Diabetes, Type 2 diabetes, Glucose, Aes, Weight loss, Clinical trial, Pharmacokinetics, SAD, Liraglutide, MSCS, Appetite, Doctor of Philosophy, Trial of the century, Blood, GPCR, University of Texas Southwestern Medical Center, DSM-IV codes, Patient, SAN, Internal medicine, Annual general meeting, Overweight, GIP, MAD, Poster, MPH, Therapy, ADA, T2D, Physician, Pharmacology, Safety, Human, Pharmaceutical industry, Medical imaging, Dietary supplement, Medical device, Philosopher's stone, T1D, MD

SAN DIEGO, June 23, 2023 (GLOBE NEWSWIRE) -- Carmot Therapeutics, Inc. (Carmot), a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases, today announced positive results from the following studies: a Phase 1 clinical trial of CT-388 assessing safety, tolerability, pharmacokinetics and pharmacodynamic activity in overweight and obese otherwise healthy participants, a mechanism of action (MOA) clinical study of CT-868 in overweight and obese adults with type 2 diabetes (T2D) to assess weight independent effects on glucose homeostasis, and a preclinical study in rodent models of type 1 diabetes (T1D) to support the effects of CT-868 as an adjunct to insulin treatment. The results are summarized in three poster presentations taking place at the American Diabetes Association (ADA) Annual Meeting (June 23-26, 2023).

Key Points: 
  • The results are summarized in three poster presentations taking place at the American Diabetes Association (ADA) Annual Meeting (June 23-26, 2023).
  • “We are extremely excited about the results from our CT-388 and CT-868 dual GLP-1/GIP receptor modulator programs to date.
  • These data warrant further clinical evaluation of CT-388, possibly with minimal to no titration, for the treatment of obesity, type 2 diabetes and other weight-related comorbidities.
  • Carmot has designed the Phase 1/2 CT-388 clinical trial to evaluate not only higher doses across longer treatment durations (e.g.

Kian Capital-backed SPATCO Energy Solutions Continues Platform Expansion with Acquisition of MSCS

Retrieved on: 
Tuesday, June 13, 2023
EV, Electric Vehicles, Other Energy, Machinery, Professional Services, Utilities, Oil, Gas, Energy, Automotive, Small Business, Other Professional Services, Finance, Manufacturing, Petro, Byline Bank, Learning, Maintenance, Partnership, Petroleum, Prym, MCSC, Business, Electronics, Genesis, MSCS, Accounting, Pulse, EBITDA, Acquisition, Walmart, Investment, Growth, Bradshaw, Construction, Management, Retail

Kian Capital-backed SPATCO Energy Solutions (“SPATCO”), a forward-thinking infrastructure services provider of innovative turnkey solutions for petroleum, environmental and EV market segments, completed the acquisition of MSCS Ltd., a Dallas-based petroleum services company providing construction, installation and maintenance services.

Key Points: 
  • Kian Capital-backed SPATCO Energy Solutions (“SPATCO”), a forward-thinking infrastructure services provider of innovative turnkey solutions for petroleum, environmental and EV market segments, completed the acquisition of MSCS Ltd., a Dallas-based petroleum services company providing construction, installation and maintenance services.
  • The acquisition expands the company’s geographic footprint into Texas after its January 2023 acquisitions of McKinney Petroleum Equipment and Petro Supply.
  • MSCS is well entrenched in the high-growth market of Texas — with operations in Dallas, Fort Worth, San Antonio and Houston — providing the ideal launchpad for SPATCO’s expansion into the state.
  • The fifth strategic acquisition of MSCS will lead to SPATCO quadrupling EBITDA since Kian’s initial 2020 investment.

4DMT Presents Positive Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial in Patients with Cystic Fibrosis at the ECFS 46th Annual Meeting

Retrieved on: 
Wednesday, June 7, 2023
DNA, Interim, Pediatrics, CET, National Jewish Health, VG, B cell, Epithelium, Clinical trial, Quality of life, MSCS, Cystic fibrosis, Cell, RNA, Cystic fibrosis transmembrane conductance regulator, ECFS, IHC, Lung, CFTR, Biomarker, Annual general meeting, Webcast, Immunohistochemistry, Patient, CF, Conference, Fatigue, Disease, Pharmaceutical industry, Vaccine, Phosphorus, MD, Medicine

ET with cystic fibrosis specialist Dr. Jennifer L. Taylor-Cousar

Key Points: 
  • ET with cystic fibrosis specialist Dr. Jennifer L. Taylor-Cousar
    EMERYVILLE, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, today announced positive interim clinical data from the 4D-710 Phase 1/2 AEROW clinical trial for the treatment of cystic fibrosis lung disease.
  • 4D-710 is comprised of our targeted and evolved vector, A101, and a codon-optimized CFTR∆R transgene and is designed for aerosol delivery to achieve CFTR expression within lung airway epithelial cells.
  • Interim data from the study will be presented in an oral presentation titled, “AAV mediated gene therapy for cystic fibrosis: Interim results from a Phase 1/2 clinical trial,” at the European Cystic Fibrosis Society (ECFS) 46th Annual Meeting held in Vienna, Austria on Thursday, June 8 at 5:00 p.m. CET (11:00 a.m.
  • “We believe that 4D-710 represents a potentially transformative new treatment for people with CF.

4DMT to Present Interim Data from 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis Lung Disease at the European Cystic Fibrosis Society (ECFS) 46th Annual Meeting

Retrieved on: 
Wednesday, May 24, 2023
Modulation, Pediatrics, CET, National Jewish Health, VG, Cohort, Epithelium, Clinical trial, MSCS, Cystic fibrosis, ECFS, AAV, CFTR, Science, Patient, Webcast, Safety, FEV1, Disease, Communications satellite, Vaccine, Pharmaceutical industry, MD, Medicine

ET

Key Points: 
  • ET
    EMERYVILLE, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, today announced an oral presentation of the interim data from the 4D-710 Phase 1/2 AEROW clinical trial for the treatment of cystic fibrosis lung disease at the European Cystic Fibrosis Society 46th Annual Meeting held in Vienna, Austria on June 7-10, 2023.
  • Clinical data will focus on safety, tolerability, pulmonary function testing (percent predicted FEV1) and respiratory-related quality of life assessments (Cystic Fibrosis Questionnaire-Revised or CFQ-R, Respiratory Domain Score).
  • The presentation will also include biomarker data on expression of the cystic fibrosis transmembrane regulator (CFTR) transgene protein from the endobronchial lung biopsies & brushings collected at week 4-8 after dosing.
  • ET to discuss the interim clinical data and provide a program update.

4DMT Announces Presentation on Aerosolized 4D-710 for Treatment of Cystic Fibrosis at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

Retrieved on: 
Thursday, May 11, 2023
Pediatrics, Gene, National Jewish Health, VG, Cohort, MSCS, Cystic fibrosis, RNA, CFTR, Science, Patient, Annual general meeting, Cell, Safety, Society, FEV1, Conference, Pharmaceutical industry, Medicine

The oral presentation will be given by Jennifer L. Taylor-Cousar, M.D., MSCS, Professor, Departments of Medicine and Pediatrics, and Co-Director, Adult Cystic Fibrosis Program, Director, Cystic Fibrosis Foundation Therapeutics Development Center, National Jewish Health.

Key Points: 
  • The oral presentation will be given by Jennifer L. Taylor-Cousar, M.D., MSCS, Professor, Departments of Medicine and Pediatrics, and Co-Director, Adult Cystic Fibrosis Program, Director, Cystic Fibrosis Foundation Therapeutics Development Center, National Jewish Health.
  • In situ hybridization biomarker data, demonstrating transgene RNA expression from lung samples from Cohort 1 patients, was previously presented by Dr. Taylor-Cousar at the North American Cystic Fibrosis Conference (NACFC), November 3, 2022.
  • Additional clinical and biomarker data for Cohort 1 patients (n=3; 9-12 months follow-up) are expected to be presented at the European Cystic Fibrosis Conference in June 2023.
  • Clinical data will focus on safety, tolerability, pulmonary function testing (e.g., percent predicted FEV1) and respiratory-related quality of life assessments.